Jonathan Schwartz, M.D.

Jonathan Schwartz, M.D.

Chief Medical and Gene Therapy OfficeratRocket Pharmaceuticals· In proxies 2021–2024

Pay in FY2024-25% from the year before · Rocket Pharmaceuticals stock -58.1% the same year

Jonathan Schwartz, M.D. was paid $2.4M in FY2024 (Dec), down 25%. Rocket Pharmaceuticals stock fell 58.1% that year.

Pay$100 in the stock at the end of FY20 → $23
Pay is from the Summary Compensation Table of each Rocket Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Rocket PharmaceuticalsPublic company · 5 yr
    • Chief Medical and Gene Therapy Officer2021 – Present · 5 yrStock in role -95%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?